Mineralys Therapeutics Inc (NASDAQ:MLYS) price on Friday, April 11, rose 9.93% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $13.40.
A look at the stock’s price movement, the close in the last trading session was $12.19, moving within a range at $11.77 and $13.53. The beta value (5-Year monthly) was -0.394. Turning to its 52-week performance, $18.38 and $8.24 were the 52-week high and 52-week low respectively. Overall, MLYS moved -0.74% over the past month.
Mineralys Therapeutics Inc’s market cap currently stands at around $869.34 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-11.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MLYS is a 50% Buy. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend MLYS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MLYS’s current price about -7.79% and 10.51% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.39, while 7-day volatility ratio is 14.29% and 10.90% in the 30-day chart. Further, Mineralys Therapeutics Inc (MLYS) has a beta value of 0.13, and an average true range (ATR) of 1.52. Analysts have given the company’s stock an average 52-week price target of $42, forecast between a low of $42 and high of $42. Looking at the price targets, the low is -213.43% off current price level while to achieve the yearly target high, price needs to move -213.43%. Nonetheless, investors will most likely welcome a -213.43% jump to $42 which is the analysts’ median price.
If we refocus on Mineralys Therapeutics Inc (NASDAQ:MLYS), historical trading data shows that trading volumes averaged 1.58 over the past 10 days and 1.07 million over the past 3 months. The company’s latest data on shares outstanding shows there are 49.82 million shares.
The 41.04% of Mineralys Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 46.19% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.22 million on 2025-03-14, giving us a short ratio of 1.38. The data shows that as of 2025-03-14 short interest in Mineralys Therapeutics Inc (MLYS) stood at 471.0 of shares outstanding, with shares short rising to 1.75 million registered in 2025-02-14. Current price change has pushed the stock 8.85% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MLYS stock continues to rise going into the next quarter.
